In today’s pharmaceutical landscape, regulatory submissions are a decisive factor in speed to market, compliance, and overall business performance. At the center of this transformation lies the electronic Common Technical Document (eCTD), which has become the global standard for submissions across major health authorities.
For companies operating in Europe, the United States, Canada, and other regulated markets, eCTD is not optional. Agencies such as the EMA, FDA, MHRA, and Health Canada require most submissions to follow this structured electronic format, in line with strict and evolving technical specifications.
Yet, while the requirement itself is clear, the way organizations approach eCTD varies widely — and this is where the real difference is made.